Abstracts Archive - Page 2282 of 2607 - ACR Meeting Abstracts

Abstract Number: 2288 • 2013 ACR/ARHP Annual Meeting
Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients
Jason Ptacek¹, Rachael Hawtin², Brent Louie¹, Erik Evensen¹, James Cordeiro¹, Barbara Mittleman¹, Michelle Atallah¹, Alessandra Cesano², Clifton O. Bingham III³, Stacey Cofield⁴, Jeffrey R. Curtis⁵, Maria I. Danila⁴, Richard A. Furie⁶, MC Genovese⁷, Marc C. Levesque⁸, Larry W. Moreland⁸, Peter A. Nigrovic⁹, James R. O'Dell¹⁰, William H. Robinson¹¹, Nancy A. Shadick⁹, E. William St Clair¹², Christopher C. Striebich¹³, Geoffrey M Thiele¹⁴, Peter K. Gregersen⁶ and S. Louis Bridges Jr.⁴, ¹Nodality, Inc., South San Francisco, CA, ²Nodality Inc., South San Francisco, CA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL, ⁶The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁷Stanford University, Palo Alto, CA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital/Harvard University, Cambridge, MA, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biomarkers reflecting immune function and associating with disease activity can help stratify rheumatoid arthritis (RA) patients (pts) in practice and in clinical trials.…
Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis
Michael Mahler¹, Gabriella Lakos¹, Tyler Webb¹, Alvin Yee¹, Leendert A. Trouw² and Pier-Luigi Meroni³, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…
Abstract Number: 2261 • 2013 ACR/ARHP Annual Meeting
Motivations For Inadequate Persistence With Disease Modifying Anti-Rheumatic Drugs In Early Rheumatoid Arthritis: The Patient’s Perspective
Virginia Pascual-Ramos and Irazú Contreras-Yáñez, Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Knowledge of factors that contribute to non-persistence with disease modifying anti-rheumatic drugs (NP-DMARDs) is essential to improve rheumatoid arthritis (RA) outcomes. Aims of the…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 2250 • 2013 ACR/ARHP Annual Meeting
What Is The Real World Relationship Between Patient-Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada
Regan Arendse¹, Michael Starr², Proton Rahman³, John T. Kelsall⁴, Milton F. Baker⁵, William Bensen⁶, J. Carter Thorne⁷, Philip Baer⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan M. Otawa¹², May Shawi¹³, Francois Nantel¹⁴ and Allen J. Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Victoria, Victoria, BC, Canada, ⁶St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes such as pain and patient global assessment of disease activity (PtGA) have been critiqued for not accurately assessing rheumatoid arthritis (RA) disease…
Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting
Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry
William G. Bensen¹, Algis V Jovaisas², J. Carter Thorne³, Philip Baer⁴, Majed M. Khraishi⁵, Sanjay Dixit⁶, Denis Choquette⁷, Michael Starr⁸, Isabelle Fortin⁹, Dalton E. Sholter¹⁰, Emmanouil Rampakakis^11,12, John S. Sampalis^11,12, Francois Nantel¹³, Allen J. Lehman¹⁴, May Shawi¹⁵ and Susan M. Otawa¹⁴, ¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸Montreal General Hospital, Montreal, QC, Canada, ⁹Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹⁰Rheumatology Associates, Edmonton, AB, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
Abstract Number: 2252 • 2013 ACR/ARHP Annual Meeting
Assessment Of Rheumatoid Arthritis Disease Activity By Patients and Physicians: Do Physicians Detect Improvement Before The Patient Does?
William G. Bensen¹, J. Carter Thorne², Philip Baer³, Andrew Chow⁴, Regan Arendse⁵, Isabelle Fortin⁶, Milton F. Baker⁷, Boulos Haraoui^8,9, Algis Jovaisas¹⁰, John S. Sampalis^11,12, Emmanouil Rampakakis^11,12, Allen J. Lehman¹³, Francois Nantel¹⁴, May Shawi¹⁵ and Susan M. Otawa¹³, ¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Private Practice, Scarborough, ON, Canada, ⁴University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁷University of Victoria, Victoria, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ¹⁰Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Patient (PtGA) and physician (MDGA) global assessment of disease activity measure the same construct from two different perspectives. The objective of this study was…
Abstract Number: 2253 • 2013 ACR/ARHP Annual Meeting
How Often Are Core Variables Reported To Calculate Common Disease Activity Scores Measured In Routine Care Of Rheumatoid Arthritis Patients?
Bindee Kuriya¹, Jessica Widdifield^2,3, Claire Bombardier⁴, Xiuing Li⁵, Binu Jacob⁶, Pooneh Akhavan⁷, J. Carter Thorne⁸, Janet E. Pope⁹, Edward C. Keystone¹⁰, William G. Bensen¹¹ and Vandana Ahluwalia¹², ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Toronto, ON, Canada, ⁶University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ⁷Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹St Joseph Health Care, London, ON, Canada, ¹⁰Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹²William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Treat-to-target (T2T) is a therapeutic strategy in rheumatoid arthritis (RA) that has been associated with improved outcomes. T2T relies on objective measurement of disease…
Abstract Number: 2254 • 2013 ACR/ARHP Annual Meeting
Complementary and Alternative Medicine in Rheumatoid Arthritis – Persistently High Use Over the Past Decade Despite Advent of Biologics
Dana DiRenzo^1,2, Haiyan Sun³, H. Lester Kirchner³ and Eric D. Newman⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴Department of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Complementary and Alternative Medicine (CAM) is commonly used when traditional medicine cannot reliably alter the disease. Over the past decade, rheumatoid arthritis (RA) treatment…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 2256 • 2013 ACR/ARHP Annual Meeting
Analysis of the Factors That Contribute to the Differences Between DAS28-ESR and DAS28-CRP
Toshihiro Matsui¹, Hirotaka Tsuno², Jinju Nishino³, Yoshiaki Kuga⁴, Atsushi Hashimoto⁵ and Shigeto Tohma⁶, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ²Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Wakaba Hospital, Saitama, Japan, ⁵Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: It is widely accepted that the remission rate of DAS28-CRP is larger than that of DAS28-ESR, SDAI, and CDAI in patients with rheumatoid arthritis.…
Abstract Number: 2257 • 2013 ACR/ARHP Annual Meeting
Symptom Complexes At The Beginning Of Rheumatoid Arthritis: A Qualitative Exploration In At Risk Individuals and In New Patients Prior To Diagnosis
Rebecca J Stack¹, Lilian H.D. van Tuyl², Maurits Sloots³, Lotte A. van de Stadt³, Wijnanda Hoogland³, Bertha Matt³, Christian D Mallen⁴, Rumandeep Tiwana¹, Karim Raza¹ and Dirkjan van Schaardenburg³, ¹Centre for Translational Inflammation Research, University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom
Background/Purpose: To achieve better prediction of the development of rheumatoid arthritis (RA) a EULAR study group recommended identification and assessment of symptoms in those with…
Abstract Number: 2258 • 2013 ACR/ARHP Annual Meeting
Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Chunqiao Luo⁴, Yvonne R. S. Sherrer⁵, Edward L. Treadwell⁶, Angelia D. Mosley-Williams⁷, Luis R. Espinoza⁸, Rodolfo Perez Alamino⁹, Sharon Dowell¹⁰, Ignacio Garcia-Vallardes¹¹, Theresa Lawrence-Ford¹², Adrian Godoy¹⁰, Akgun Ince¹³ and Cindy Flower¹⁴, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²New York University Hospital for Joint Diseases, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁶Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁷John Dingell VAMC, Detroit, MI, ⁸Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁹Rheumatology, Lousiana State University and LSU Medical Center, New Orleans, LA, ¹⁰Division of Rheumatology, Howard University, Washington, DC, ¹¹Rheumatology Clinical Practice, Guadalajara, Gaudalajara, Mexico, ¹²North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹³Arthitis Consultants Inc, Saint Louis University, St. Louis, MO, ¹⁴Medicine, University of the West Indies, Bridgetown, Barbados
Background/Purpose: RCT are the gold standard for therapeutic efficacy, yet many studies indicate most patients seen in routine clinical care do not meet inclusion criteria.…
Abstract Number: 2259 • 2013 ACR/ARHP Annual Meeting
Does a Ratingen Score Of ≥ 3 At Disease Onset Define RA In ACR/EULAR 2010 Criteria Negative Patients?
Ruediger Mueller¹, Toni Kaegi¹, Sarah Haile² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: A EULAR task force has recently selected an evidence and consensus based definition of erosive disease defining rheumatoid arthritis (RA) in patients who do…
Abstract Number: 2260 • 2013 ACR/ARHP Annual Meeting
Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis
Bjorn Svensson¹, Ingiäld Hafström², Malin Erlandsson³, Kristina Forslind⁴ and Maria Bokarewa³, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden
Background/Purpose: High levels of the oncoprotein survivin may be detected in the majority of patients with early rheumatoid arthritis (RA). Survivin is a sensitive predictor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].